Abbott Laboratories filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting third-quarter net sales of $13.013 billion and net earnings of $920 million.

Key Highlights

  • Net sales: $13.013 billion for Q3 2026, compared with $11.369 billion in Q3 2025.
  • Net earnings: $920 million for Q3 2026, compared with $1.644 billion in Q3 2025.
  • Diluted EPS: $0.53 for Q3 2026, compared with $0.94 in Q3 2025.
  • Nine-month net sales: $36.770 billion for the nine months ended September 30, 2026, versus $32.869 billion for the same period in 2025.
  • Total assets: $108.247 billion as of September 30, 2026, up from $86.713 billion at December 31, 2025.
  • Long-term debt: $29.451 billion as of September 30, 2026, compared with $9.896 billion at December 31, 2025.
  • Common shares outstanding: 1,731,941,601 as of September 30, 2026.

Abbott Laboratories Third-Quarter 2026 Financial Results and Balance Sheet Changes

According to the filing, Abbott Laboratories (NYSE:ABT) reported net sales of $13.013 billion for the three months ended September 30, 2026, an increase from $11.369 billion in the same quarter of 2025. Operating earnings for the quarter were $1.358 billion, compared with $2.057 billion in Q3 2025. The company disclosed that amortization of intangible assets rose to $841 million in Q3 2026 from $420 million in Q3 2025, and selling, general, and administrative expenses increased to $4.266 billion from $3.051 billion over the same period.

For the nine months ended September 30, 2026, the registrant reported net sales of $36.770 billion and net earnings of $2.925 billion, compared with $32.869 billion and $4.748 billion, respectively, for the nine months ended September 30, 2025. Diluted earnings per common share for the nine-month period were $1.67 in 2026 versus $2.70 in 2025, according to the filing. Interest expense for the nine-month period was $875 million in 2026, compared with $373 million in 2025.

The condensed consolidated balance sheet showed total assets of $108.247 billion as of September 30, 2026, versus $86.713 billion at December 31, 2025. The filing disclosed significant increases in goodwill, rising to $32.643 billion from $24.035 billion, and in net intangible assets, rising to $19.591 billion from $5.526 billion, over the same period. Long-term debt increased to $29.451 billion from $9.896 billion. Cash and cash equivalents decreased to $4.052 billion from $8.522 billion at year-end 2025. The company declared cash dividends of $0.63 per common share in Q3 2026, compared with $0.59 per common share in Q3 2025, as disclosed in the statement of shareholders' investment.

What Was Disclosed

Abbott Laboratories disclosed its unaudited condensed consolidated financial statements for the quarter and nine months ended September 30, 2026, covering earnings, comprehensive income, balance sheet position, cash flows, and shareholders' investment, along with notes and management's discussion.